Ethic Inc. Boosts Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Ethic Inc. grew its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 422.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,073 shares of the company's stock after purchasing an additional 18,655 shares during the quarter. Ethic Inc.'s holdings in Dr. Reddy's Laboratories were worth $364,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of RDY. Deutsche Bank AG lifted its stake in Dr. Reddy's Laboratories by 311.9% in the fourth quarter. Deutsche Bank AG now owns 171,602 shares of the company's stock valued at $2,710,000 after buying an additional 129,936 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its stake in Dr. Reddy's Laboratories by 256.3% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 429,887 shares of the company's stock worth $6,788,000 after purchasing an additional 309,239 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in Dr. Reddy's Laboratories by 400.0% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 400,000 shares of the company's stock valued at $6,316,000 after purchasing an additional 320,000 shares during the period. Cetera Investment Advisers grew its holdings in shares of Dr. Reddy's Laboratories by 410.5% during the fourth quarter. Cetera Investment Advisers now owns 20,720 shares of the company's stock worth $327,000 after buying an additional 16,661 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its position in Dr. Reddy's Laboratories by 781.7% in the 4th quarter. Balyasny Asset Management L.P. now owns 103,850 shares of the company's stock valued at $1,640,000 after acquiring an additional 92,071 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy's Laboratories Price Performance

Shares of NYSE:RDY traded down $0.06 during trading on Thursday, hitting $14.28. 239,400 shares of the stock were exchanged, compared to its average volume of 1,489,151. The company has a market cap of $11.92 billion, a PE ratio of 22.73 and a beta of 0.33. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average price of $13.54 and a two-hundred day moving average price of $14.03. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. The business had revenue of $996.17 million during the quarter, compared to analysts' expectations of $83.70 billion. On average, analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.